A retrospective, real-world study of regorafenib versus nivolumab in patients with hepatocellular carcinoma after sorafenib failure
Latest Information Update: 20 Oct 2020
At a glance
- Drugs Nivolumab (Primary) ; Regorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 20 Oct 2020 New trial record
- 29 Aug 2020 Results presented at The International Liver Congress 2020